Citadel Advisors’s SOPHiA GENETICS SOPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,800
Closed -$12.6K 14897
2025
Q1
$12.6K Buy
3,800
+3,300
+660% +$11.6K ﹤0.01% 13434
2024
Q4
$1.56K Buy
500
+200
+67% +$681 ﹤0.01% 14174
2024
Q3
$1.09K Buy
+300
New +$1.22K ﹤0.01% 13902
2023
Q4
Sell
-100
Closed -$255 15180
2023
Q3
$255 Buy
+100
New +$317 ﹤0.01% 14110

Other funds holding SOPH

Citadel Advisors's SOPH Position: Q4 2025 in Review

Citadel Advisors sold out of SOPHiA GENETICS (SOPH) in Q4 2025, closing a stake of 12,320 shares — an estimated $58.6K sold.

Citadel Advisors first reported a position in SOPH in Q4 2021 and held it in 12 quarters. The position peaked at $334K in Q1 2023. 42 funds tracked by Wall St. Rank hold SOPH as of Q4 2025.

  • Citadel Advisors reported no remaining SOPHiA GENETICS position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,320 SOPHiA GENETICS shares in Q4 2025, an estimated $58.6K.
  • Citadel Advisors first reported a position in SOPHiA GENETICS in Q4 2021 and held it in 12 quarters.
  • Citadel Advisors's SOPHiA GENETICS position peaked at $334K in Q1 2023.
  • 42 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.